SEC Form 4 · accession 0001193125-26-381953
NewAmsterdam Pharma Co N.V. · NAMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert William Gunning
Officer — Vice President, Controller
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001936258
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Sep 1, 2026 | A | 3,200 | $0.00 | A | 3,200 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2 | $24.92 | Sep 1, 2026 | A | 14,000 | A | — | Aug 31, 2036 | Ordinary Shares | 14,000 | 14,000 | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, September 10, 2026, subject to the Reporting Person's continued service through each such date.
- F225% of the shares underlying the option will vest on August 10, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.